This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Chinese Pharma Looks Healthy as Price Controls Ease, Consumers Spend More

BEIJING (TheStreet) -- Long lines of patients snaking through China's overcrowded hospitals offer living proof of the huge potential for health care companies on the mainland.

Much of that potential could be realized over the next few years as consumers grow wealthier and the government eases market controls, according to analysts who follow China's pharmaceutical and medical supply sectors.

A milestone for the nation's health care market will be reached in June if government regulators introduce what market watchers expect will be a new, looser price control regime for drugs, according to separate reports released this week by Bank of China International, Essence Securities and Guangzheng Hang Seng Securities.

Moreover, observers say the government is wrapping up a year-long anti-corruption sweep of the pharmaceutical sector. The crackdown led to bribery charges last year against Chinese subsidiaries of multinational drug makers Novartis (NVS) and GlaxoSmithKline (GSK).

Health care companies are seeing their businesses improve as government watchdogs back off, analysts say. A report by the China division of Goldman Sachs described the changing environment this way: "Most companies expect sequential recovery from the anti-corruption campaign, with accelerated top-line growth in 1H 2014."

Companies are also adjusting as the government encourages market forces to play a larger role in setting prices.

Regulators have apparently decided to give pharmaceutical companies more room to raise prices after "recognizing deficiencies in the existing mechanisms for drug pricing," the Essence report said. The firm based its conclusions on recent "actions and statements" by the government's economic planner, the National Development and Reform Commission.

The commission's "drug price management policy ideas have significantly changed," the report said, adding that "benchmark pricing" for drugs could be introduced by the government.

Bank of China analysts agreed that "a softer policy stance is expected in 2014 on the back of the government's thorough reviews of (its) previous, stringent policies."

A wide range of medical services, drugs and supplies have been tightly controlled for decades under China's partially socialized health care system. Price caps, however, have been blamed for all kinds of off-the-books activity, such as cash "gifts" handed to surgeons by patients who want to butt in line and bribes paid to hospital staffers by pharmaceutical salesmen.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,031.14 +43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASDAQ 4,518.9020 -48.6960 -1.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs